We're excited to announce the combination of Berkeley Lights and IsoPlexis, bringing together the Beacon and IsoSpark platforms to form the premier functional cell biology company. Visit Site

Employing IsoPlexis' PSI™ to Summarize Complex Single-cell Cytokine Data

See how PSI correlates with the objective response across cancer immunotherapies and is accelerating discovery and development.

Your data is secure

We keep your personal information safe and do not share it with any third parties. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy. You may unsubscribe at any time.

What's Inside

In this we discuss:

Polyfunctionality alone is a meaningful indicator of potency in a variety of immunotherapy types, including CAR T therapy, where PSI has significantly outperformed other pre-infusion metrics
Many researchers are also using sub-components of the PSI to develop a sub-component polyfunctional strength cell subset driver, such as IL-17 or Stimulatory driven Polyfunctional Strength
The PSI Index reveals aggregate differences that guide your deep dive into polyfunctional cell subsets, via single-cell heat maps and cellular analyses like PAT PCA and t-SNE, that can reveal biomarkers and development insights
A Deeper Look

More about this

IsoPlexis’ Polyfunctional Strength Index (PSI)

PSI is a powerful, novel metric for measuring the potency of a variety of immune cell types in cancer immunotherapy, based on the ability to uniquely isolate & detect potent functional cell subsets.

PSI is generated by identifying the polyfunctional single cells (those cells secreting two or more cytokines) and measuring the intensity of the cytokines they secrete.

Download this Tech Note to learn how PSI helps you accelerate research!

Get the